Industry News
Biotechnology Industry News

Boston biotech backers quit Dana-Farber board after U-turn on investment policy: report
Boston biotech backers quit Dana-Farber board after U-turn on investment policy: report ntaylor Tue, 10/12/2021 - 07:51
CureVac giving up on first COVID mRNA vax, focusing on GSK-partnered 2nd attempt
CureVac giving up on first COVID mRNA vax, focusing on GSK-partnered 2nd attempt badams Tue, 10/12/2021 - 07:29
A New Way to Access Scientific Papers?
A New Way to Access Scientific Papers? admin Mon, 10/11/2021 - 15:38
Brain atlas unveils dozens of cell types that control movement and could inspire targets in neurological disease
Brain atlas unveils dozens of cell types that control movement and could inspire targets in neurological disease arlene.weintraub Mon, 10/11/2021 - 08:50
Protagonist’s story gets a happy ending as FDA’s hold swiftly lifted on rusfertide program
Protagonist's story gets a happy ending as FDA's hold swiftly lifted on rusfertide program badams Mon, 10/11/2021 - 08:03
Merck makes beeline to FDA, seeking approval for COVID-19 antiviral 10 days after reporting data
Merck makes beeline to FDA, seeking approval for COVID-19 antiviral 10 days after reporting data ntaylor Mon, 10/11/2021 - 07:29
AstraZeneca’s COVID-19 therapy hits goal in phase 3, but efficacy falls short of rivals
AstraZeneca's COVID-19 therapy hits goal in phase 3, but efficacy falls short of rivals ntaylor Mon, 10/11/2021 - 05:10
Senate to cull Biden’s biomedical research agency from social care bill: Report
Senate to cull Biden's biomedical research agency from social care bill: Report badams Mon, 10/11/2021 - 04:03
Novel vaccine strategy protects mice from COVID-19 and 4 related coronaviruses
Novel vaccine strategy protects mice from COVID-19 and 4 related coronaviruses arlene.weintraub Fri, 10/08/2021 - 08:48
Pfizer, Bayer-backed Pyxis ups IPO price as biotech’s public run continues unabated
Pfizer, Bayer-backed Pyxis ups IPO price as biotech's public run continues unabated badams Fri, 10/08/2021 - 08:12
Takeda’s transplant drug gets unanimous support of FDA AdComm despite concerns over diversity of its study
Takeda's transplant drug gets unanimous support of FDA AdComm despite concerns over diversity of its study ntaylor Fri, 10/08/2021 - 05:07
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach badams Fri, 10/08/2021 - 03:58
FDA stops all Allogene’s CAR-T trials over safety scare, raising questions about future of gene editing
FDA stops all Allogene's CAR-T trials over safety scare, raising questions about future of gene editing ntaylor Fri, 10/08/2021 - 03:48
Bristol Myers Squibb’s deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster ntaylor Thu, 10/07/2021 - 08:09
Denali makes ALS play, hustling Sanofi-partnered drug into phase 2 and sharing early data on internal program
Denali makes ALS play, hustling Sanofi-partnered drug into phase 2 and sharing early data on internal program ntaylor Thu, 10/07/2021 - 04:33
Meet Neumora, Arch’s $500M, Amgen-partnered play for the targeted future of neuroscience R&D
Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D ntaylor Wed, 10/06/2021 - 11:05
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
Dengue compound backed by J&J shows potency against the virus and all known variants in mice arlene.weintraub Wed, 10/06/2021 - 10:21
EQRx’s affordable drug drive leads to Absci discovery pact
EQRx's affordable drug drive leads to Absci discovery pact ntaylor Wed, 10/06/2021 - 08:11
Yale spinout shows how targeting cancer cells’ acidic environment might enhance immunotherapy
Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy aliu Wed, 10/06/2021 - 07:38
Voyager Therapeutics looks to shake off a tough year as it pens Pfizer gene therapy pact worth $630M
Voyager Therapeutics looks to shake off a tough year as it pens Pfizer gene therapy pact worth $630M badams Wed, 10/06/2021 - 05:08

